Etanercept for therapy‐resistant macrophage activation syndrome
Copyright policy )Etanercept for therapy‐resistant macrophage activation syndrome
AbstractMacrophage activation syndrome (MAS) is a severe, potentially fatal complication of childhood rheumatic diseases, especially systemic onset juvenile idiopathic arthritis (SoJIA). We report a 4‐year‐old girl with probable SoJIA who presented with MAS. She did not respond to pulse methyl prednisolone and Cyclosporine A (CsA). She also failed to respond to intravenous immunoglobulin (IVIG) therapy. Etanercept was started, based on the observation of increased serum levels of tumor necrosis factor‐alpha (TNF‐α) in patients with MAS. Her condition improved following etanercept, suggesting that etanercept might have a therapeutic role in resistant MAS. Pediatr Blood Cancer 2008;50:419–421. © 2006 Wiley‐Liss, Inc.
Child, Preschool, Immunoglobulin G, Humans, Female, Macrophage Activation, Lymphohistiocytosis, Hemophagocytic, Receptors, Tumor Necrosis Factor, Etanercept
Child, Preschool, Immunoglobulin G, Humans, Female, Macrophage Activation, Lymphohistiocytosis, Hemophagocytic, Receptors, Tumor Necrosis Factor, Etanercept
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).52 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!